Evaluation of efficacy and safety of tralokinumab in patients with active, moderate-to-severe ulcerative colitis

Inclusion Criteria

• - Diagnosed ulcerative colitis at least 90 days prior randomisation.
• - Men or women age 18 - 75 years.
• - Non-hospitalized patients with moderate-severe ulcerative colitis treated with stable background UC therapy (e.g. containing 5-aminosalicylates, and/or low dose of glucocorticosteroids, and/or purine analogue) prior to randomization.
• - Females of childbearing potential who are sexually active with a nonsterilized male partner must use highly effective contraception from Day1.
• - Nonsterilized males or sterilized males who are ≤1 year post-vasectomy who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception.